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Abstract: 
Gram-negative microorganisms are a significant cause of infection in both 
community and nosocomial settings. The increase, emergence and spread 
of antimicrobial resistance among bacteria is one of the most important 
health problems worldwide. One of the mechanisms of resistance used by 
bacteria is biofilm formation which is also a mechanism of virulence. This 
study analyzed the possible relationship between antimicrobial resistance 
and biofilm formation among isolates of three Gram-negative bacteria 
species. Several relationships were found between the ability to form 
biofilm and antimicrobial resistance, being different for each species. 
Indeed, gentamicin and ceftazidime resistance was related to biofilm 
formation in Escherichia coli, piperacillin/tazobactam and colistin in 
Klebsiella pneumoniae, and ciprofloxacin in Pseudomonas aeruginosa. 
However, no relationship was observed between global resistance or 
multidrug-resistance and biofilm formation. In addition, compared to other 
reported data, the isolates in the present study showed higher rates of 
antimicrobial resistance. In conclusion, the acquisition of specific 
antimicrobial resistance can compromise or enhance biofilm formation in 
several species of Gram-negative bacteria. However, multidrug-resistant 
isolates do not show a trend to being greater biofilm producers than non-
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The rise in the emergence and spread of antimicrobial resistance among the different 22 
microorganisms (bacteria, fungi, virus, and parasites) is one of the most important 23 
health problems worldwide today. Resistance to antibiotics is increasing at both 24 
community and hospital levels, being especially relevant in hospital settings in which 25 
strong selective pressure favors the selection, persistence and maintenance of resistant, 26 
multi-drug-resistant (MDR) and even pan-resistant strains (resistant to all the current 27 
groups of antibiotics for therapeutic use) causing antibiotic treatment failure, increased 28 
mortality and morbidity, and having a significant impact on the cost of medical 29 
treatment and prevention of  bacterial infectious diseases.1,2 It has been estimated that 30 
the annual cost due to antimicrobial-resistant Staphylococcus aureus infections is about 31 
$4.6 billion only in USA.3  32 
Bacterial resistance to antibiotics is primarily the consequence of a variety of 33 
phenomena such as alteration of the target of the drug, impermeability of the bacteria to 34 
the antibiotic, and genetically-associated changes (mutational events, genetic transfer of 35 
resistance genes via plasmids, and mutations of target genes).4 However, this is not the 36 
only reason for antimicrobial treatment failure. In fact, the ability to form communities 37 
called biofilms embedded in an exopolysaccharide matrix is one of the mechanisms of 38 
resistance used by bacteria to survive in the presence of an antibiotic.5 In this state, 39 
bacteria can be up to 1,000-fold more resistant to antibiotics than those in a planktonic 40 
state.6-8 Several studies recommend combined antibiotic therapy as the treatment of 41 
choice in biofilm-associated infections caused by Gram-negative bacteria, with 42 
macrolides (erythromycin, clarithromycin and azithromycin) being the main antibiotics 43 
chosen due to their high antibiofilm activity in vitro and in vivo.9 However, antibiotic 44 
treatment of biofilm-associated infections requires further study, since the selection of a 45 
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specific treatment is difficult because of the wide variability of the microorganisms 46 
involved. 47 
Several studies have demonstrated that low doses of certain antibiotics can induce 48 
biofilm formation indicating that biofilm regulation includes the presence of antibiotics.  49 
However, the correlation between biofilm formation and antibiotic resistance is 50 
currently unclear and remains under investigation.10,11 51 
Previous studies carried out in our laboratory showed a relationship between the 52 
acquisition of resistance (specifically resistance to quinolones) and the ability to form 53 
biofilm12 among uropathogenic Escherichia coli (UPEC). It was found that a decrease 54 
in biofilm formation was mainly due to a decrease of type 1 fimbriae expression13. 55 
However, more studies are needed to elucidate this relationship in other bacteria. 56 
Thus, the aim of this study was to anal ze the possible relationship between the ability 57 
to form biofilm and antimicrobial resistance among susceptible, resistant and multidrug-58 
resistant Gram-negative clinical isolates from different hospitals in Catalonia. 59 
  60 
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MATERIAL AND METHODS 61 
Bacteria. Four hundred eight bacterial isolates were collected from four Catalan 62 
hospitals (Hospital Clinic of Barcelona, Hospital Universitario de Bellvitge, Hospital 63 
del Mar, and Hospital Universitario Mutua de Terrassa) over a 6-month period from 64 
2016-2017. Among these, 142 were E. coli, 117 Klebsiella pneumoniae, and 149 were 65 
Pseudomonas aeruginosa. The bacteria were isolated from blood, urine and respiratory 66 
(including, sputum and tracheal aspirate) samples and processed at the corresponding 67 
Microbiology Laboratory. All the isolates were confirmed by matrix-assisted laser 68 
desorption ionization-time of flight mass spectrometry (MALDI-TOF) and were stored 69 
in skim milk (BD) at -80ºC. The samples used in our study were sourced through 70 
institutional tissue repositories.  71 
Analysis of antimicrobial resistance. Resistance profiles were determined using the 72 
standard Kirby-Bauer disk-diffusion method following the Clinical & Laboratory 73 
Standards Institute (CSLI) guidelines.14 E. coli ATCC 25922 and P. aeruginosa ATCC 74 
27853 strains were used as controls. The antimicrobial agents tested were: amikacin (30 75 
µg), amoxicillin/clavulanic acid (30 µg), ceftazidime (30 µg), cefepime (30 µg), 76 
imipenem (10 µg), meropenem (10 µg), trimethoprim-sulfamethoxazole (30µg), 77 
gentamicin (10µg), tobramycin (10 µg), ciprofloxacin (5 µg), chloramphenicol (30 µg), 78 
aztreonam (15 µg), piperacillin/tazobactam (100/10 µg), fosfomycin (200 µg), 79 
tigecycline (15 µg) and colistin (10 µg).  80 
Biofilm formation. Biofilm formation was analyzed using a modified protocol 81 
previously described by O’Toole et al15. Briefly, all isolates were cultured in aerobic 82 
conditions in Luria Bertani (LB) agar (Condalab) for 24 h at 37ºC to obtain single 83 
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colonies. These colonies were established by the direct colony suspension method in LB 84 
broth for 24 h at 37ºC with shaking at 180 rpm.  85 
The Biofilm formation assay was tested in 96-well microtiter plates using an 86 
appropriate medium, M63 medium in E. coli strains and LB for P. aeruginosa and K. 87 
pneumoniae, both mediums supplemented with 0.25% glucose. The plates were 88 
inoculated with the overnight culture diluted 1:100 in fresh medium and incubated for 89 
24 h at 37ºC or 24 h at 30ºC in case of E. coli strains, both in static conditions. The final 90 
volume of liquid in each well was 200 µL. All plates include a sterility control (culture 91 
medium without inoculum) and a growth control (control medium with inoculum). To 92 
avoid evaporation, all plates were covered with adhesive foil lids. 93 
The biofilm formation assay for P. aeruginosa was performed using the Calgary 94 
protocol as described previously16 ). The bacterial biofilm was formed by immersing the 95 
pegs of a modified polystyrene microtiter lid into a 96-well microtiter plate containing 96 
200 µL of the ON culture diluted 1:100 in fresh LB medium (catalog no. 445497; Nunc 97 
TSP system, Nunc, Roskilde, Denmark).  98 
Biofilm quantification  99 
After incubation, liquid culture was carefully removed and washed once with 210 µL of 100 
PBS and dried at 65ºC until complete desiccation. Biofilms were stained with 200 µL of 101 
1% (v/v) solution of crystal violet (CV) stain and incubated 10 min at room 102 
temperature. Afterwards, CV stain was completely removed, washing once with 210 µL 103 
of PBS and heat-fixed at 65ºC for 60 min.  104 
 105 
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The CV was eluted by the addition of 200 µL of 33% glacial acetic acid. The optical 106 
density (OD) was measured at 580 nm using a Microplate reader (EPOCH 2 microplate 107 
reader, BioTek, VT, USA).  108 
Biofilm classification 109 
In this study, the heterogeneity in the biomass of the samples requires definition of a 110 
cut-off value that would divide the samples in non-adherent, weakly, moderately and 111 
strongly-adherent. For this reason, all samples were tested in triplicate and calculated 112 
the OD average using negative controls (medium without inoculum). The cut-off value 113 
was defined for each species. For easier interpretation of the results, strains were 114 
classified into the following categories using an adaptation of a previous study17): 115 
The isolates were categorised in quartiles according OD value using Graphpad Prism 5. 116 
The quartile below 25% percentile were classed as non-adherent 117 
(OD580 = 0.0640,0.1605 and 0.3145 for E. coli, K. pneumoniae and P. aeruginosa, 118 
respectively). If their biomass absorbances were compressed between 25% percentile 119 
and Median (0.1920, 0.2560, 0.5560 for E. coli, K. pneumoniae and P. aeruginosa, 120 
respectively) as weakly adherent. Value between the median and 75% Percentile 121 
(0.4165, 0.3765, 0.8080 for E. coli, K. pneumoniae and P. aeruginosa, respectively) 122 
were classified as moderate adherent and the isolate with OD over 75 % percentile were 123 
deemed as strong biofilm producer. According to OD value of positive control of each 124 
microorganism were categorized as strong biofilm.  125 
Statistical analysis. Chi-square test and Spearman’s rank correlation test was 126 
performed by SPSS 24.0 for Windows) were used for study de association and 127 
correlation between biofilm formation among and antimicrobial susceptibility 128 
categories and the respective origin of microorganisms  129 
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Approximately 40% of all the isolates studied were resistant to ciprofloxacin. In 131 
addition, 50% of the E. coli isolates were resistant to cotrimoxazol, 36% of K. 132 
pneumoniae were resistant to ceftazidime, and about 30% of the P. aeruginosa isolates 133 
were resistant to imipenem, meropenem, azthreonam and fosfomycin (Figure 1). 134 
According to the number of antibiotic families to which the isolates were resistant, they 135 
were classified into susceptible (S - not resistant to any family), resistant (R -resistant to 136 
1-2 categories), multidrug-resistant (MDR - resistant to 3 or more antibiotic families) 137 
and extensively drug-resistant (XDR - non-susceptible to at least one agent in all but 138 
two or fewer antimicrobial categories (i.e., bacterial isolates remained susceptible to 139 
only one or two categories)) Thus, 35% of all the isolates were S, 35% were R, and 30% 140 
were MDR (data not shown). Among the E. coli isolates, 29% were S, 41% R and 30% 141 
MDR. In the case of K. pneumoniae, 29%, 33% and 38% were S, R and MDR, 142 
respectively. Finally, 41%, 31%, 19% and 9% of P. aeruginosa isolates were S, R, 143 
MDR and XDR (Figure 1). 144 
On analysis of the antimicrobial resistance of each species according to the type of 145 
sample (blood, respiratory and urine), several differences were found. K. pneumoniae 146 
isolates collected from blood were less resistant to fosfomycin than those collected from 147 
sputum and urine (1.7% vs. 9.4% and 13.7%, respectively). P. aeruginosa isolates 148 
collected from respiratory were, in general, more resistant to all the antimicrobial agents 149 
studied in common in the three species than their counterparts isolated from blood and 150 
urine (Table 1). 151 
We studied the ability of all the isolates collected to form biofilm in vitro and found that 152 
49.3% were able to do so: 30.3% of the E. coli, 37.6% of K. pneumoniae and 76.5% of 153 
P. aeruginosa isolates, respectively.  154 
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No significant differences were found in the frequency of biofilm forming isolates in 155 
relation to each type of sample (blood, sputum and urine). However, some trends were 156 
observed. For example, in the case of E. coli, the isolates collected from respiratory 157 
were less biofilm forming than those collected from blood or urine On the other hand, 158 
the P. aeruginosa isolates collected from respiratory were more biofilm forming than 159 
those from the other types of samples (Figure 2)   160 
Relationships between the ability to form biofilm and antimicrobial resistance were 161 
scarce and differed for each species. In the case of K. pneumoniae, the isolates resistant 162 
to colistin showed a strong capacity to form biofilm than the susceptible isolates (p= 163 
0.026) and the biofilm formation was strong in P. aeruginosa isolates susceptible to 164 
ciprofloxacin than in their resistant counterparts (p= 0.041) (Table 1). 165 
Finally, there was no significant relationship between global resistance or multidrug-166 
resistance and biofilm formation. However, the P. aeruginosa isolates susceptible to all 167 
the antibiotics studied or resistant to only 1 antimicrobial category tended to be more 168 




Gram-negative microorganisms are a significant cause of infection in both community 173 
and nosocomial settings.18 The emergence of microorganisms resistant to multiple 174 
antibiotics used in the treatment of infections has become an important health problem 175 
worldwide. The present study analyzed three species of microorganisms included 176 
among the ESKAPE pathogens: K. pneumoniae and P. aeruginosa, as well as E. coli 177 
isolates. 178 
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The percentage of isolates resistant to the different antibiotics studied was higher in 179 
comparison with other studies (Table 3). 180 
It was of note that the hospitals participating in this study showed higher rates of 181 
ciprofloxacin resistance ranging from 37% to 45% compared to other studies reporting a 182 
rate of resistance of less than 29%. The high percentage of resistance found among the 183 
isolates collected from blood in the hospitals participating in the study could be due to 184 
the fact that patients had received antimicrobial treatment before the sample was 185 
obtained. It is also well known that the misuse of antibiotics leads to selective pressure 186 
that favors the acquisition of resistance. We evaluated the possible relationship between 187 
antimicrobial resistance and the ability to form biofilm among the collected isolates. No 188 
relationship was found between multidrug-resistance and biofilm formation, but similar 189 
to other studies19 we found a comparable level of biofilm production in both multidrug 190 
and non-multidrug resistant isolates with no significant differences between the two 191 
groups. High rates of biofilm producing K. pneumoniae have been reported in 192 
multidrug-resistant strains, mainly ESBL producers harboring blaCTX-M genes.
20 193 
However, there are reports regarding relationships between biofilm formation and 194 
resistance to specific antibiotics. Thus, the acquisition of quinolone resistance has been 195 
related to a decrease in biofilm production in both uropathogenic E. coli and Salmonella 196 
typhimurium.12,21 In the present study, we also found this relationship between 197 
quinolone resistance and biofilm formation in P. aeruginosa, with the susceptible 198 
isolates showing a greater capacity to form biofilm than the resistant isolates. However, 199 
there are discrepancies among the different studies in the literature. One example of this 200 
is the study of the effect of meropenem resistance on biofilm formation. Several studies 201 
found that the strains resistant to meropenem showed Gram-negative bacteria to have a 202 
greater capacity to form biofilm22 in contrast to other studies that found an inverse 203 
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relationship between meropenem resistance and biofilm formation among other Gram-204 
negative bacteria such as Acinetobacter baumannii.23 Resistance to imipenem has been 205 
associated with less biofilm production in P. aeruginosa isolates
24
, although we did not 206 
observe this association. This is the first time that a relationship between gentamicin 207 
resistance and biofilm formation has been reported in E. coli.  208 
 209 
In conclusion, the acquisition of specific antimicrobial resistance can compromise or 210 
enhance biofilm formation in several species of Gram-negative bacteria. However, 211 
multidrug-resistant strains did not tend to have greater biofilm production than non-212 
multiresistant isolates. Further studies are needed to determine how the acquisition of 213 
gentamicin resistance affects biofilm formation. 214 
 215 
 216 
  217 
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FIGURE LEGENDS 1 
Figure 1. Percentages of isolates resistant to the different antibiotics used in the 2 
treatment of each microorganism (A: E. coli, B: K. pneumoniae, and C: P. aeruginosa)   3 
MDR: multidrug-resistant and XDR: extensively drug-resistant. 4 
 5 
Figure 2. Relationship between origin of microorganism and biofilm forming capacities 6 
 7 
Figure 3. Distribution of biofilm formation of isolate with different resistance 8 
phenotype.  9 
MDR: multidrug-resistant; XDR: extensively drug-resistant. 10 
The distribution was separate in quartile according OD580 value. The OD range of 11 
positive control biofilm is between 0.8-1. 12 
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 Table 1. Percentage of susceptibly of microorganisms isolate from blood, respiratory and urine against different antimicrobials in common 
used in this study. 
 
 
  E. coli K. pneumoniae P. aeruginosa 
  S % R% p-value ρ S% R% p-value ρ S% R% p-value Ρ 
Ceftazidime Blood 26.8 4.2   16.2 9.4   13.4 2.7   
 Respiratory 35.2 1.4   20.5 7.7   59.1 3.4   
 Urine 31.7 0.7 0.054 -0.186 36.8 9.4 0.267 -0.148 15.4 6 0.002* 0.142 
Imipenem Blood 100 0   25.6 0   10.1 6   
 Respiratory 100 0   16.5 1.7   51 11.4   
 Urine 100 0 a a 46.2 0 0.075 -0.050 13.4 8.1 0.033* 0.03 
Gentamicin Blood 28.2 2.8   22.2 3.4   10.7 5.4   
 Respiratory 28.2 8.5   25.6 2.6   51 11.4   
 Urine 27.5 4.9 0.175 0.063 36.8 9.4 0.344 0.103 14.8 6.7 0.152 0.007 
Ciprofloxacin Blood 16.9 14.1   16.2 9.4   10.7 5.4   
 Respiratory 16.2 20.4   18.8 9.4   45.6 16.8   
 Urine 20.4 12 0.174 -0.071 29.1 17.1 0.936 0.011 12.8 8.7 0.335 0.063 
Aztreonam Blood 26.8 4.2   17.1 8.5   13.5 2.7   
 Respiratory 35.5 2.1   20.5 7.7   55.4 6.8   
 Urine 31 1.4 0.206 -0.137 34.2 12 0.762 -0.062 17.6 4.1 0.471 0.032 
Piperacillin/ tazobactam Blood 31 0   20.5 5.1   14.1 2   
 Respiratory 35.9 0.7   18.8 11   55 7.4   
 Urine 32.4 0 0.418 -0.002 43.6 2.6 0.003* -0.216 17.4 4 0.606 0.063 
Fosfomycin Blood 31 0   23.9 1.7   8.1 8.1   
 Respiratory 36.6 0   18.8 9.4   49 13.4   
 Urine 31 1.4 0.120 0.148 32.5 13.7 0.027* 0.180 12.1 9.4 0.005* -0.004 
Colistin Blood 28.9 2.1   23.1 2.6   14.8 1.3   
 Respiratory 35.9 0.7   27.4 0.9   59.7 2.7   
 Urine 31.7 0.7 0.360 -0.099 41 5.1 0.403 0.045 18.8 2.7 0.262 0.067 
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Susceptible (S), Resistant (R), Spearman´s rank correlation coefficient (ρ), No statistics have been calculated (a). 
* Statically significant (p < 0.05). 
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Table 2. Relationship between biofilm formation and antimicrobial resistance. 
 p-value (> 0.05) 
Antimicrobials E. coli K. pneumoniae P. aeruginosa 
Amikacin ND ND 0.561 
Gentamicin 0.133 0.826 0.254 
Tobramycin ND ND 0.607 
Amoxicillin/clavulanic 0351 0.713 ND 
Piperacillin/Tazobactam 0.397 0.118 0.128 
Ceftazidime 0.109 0.396 0.580 
Cefepime ND ND 0.161 
Imipenem 1 0.572 0.861 
Meropenem ND ND 0.775 
Ciprofloxacin 0.06 0.898 0.041* 
Fosfomycin 0.113 0.148 0.935 
Aztreonam 0.780 0.310 0.428 
Colistin 0.639 0.026* 0.128 
Chloramphenicol 0.448 0.3 ND 
Tigecyclin 0.669 0.098 ND 
Cotrimoxazol 0.783 0.667 ND 
ND, Not determined 
* Statically significant (p < 0.05). 
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Gentamicin - 9.6 7.5 - 34.8 
Amikacin 7.12 - - - - 
Piperacillin/Tazobactam 7.49 11 3.2 3.9 0.2 
Cotrimoxazol - - 29.2 34.30 15.9 
Ceftazidime - 11.1 4.4 24 2.2 
Ciprofloxacin - 18.7 10.4 28.8 16.2 
Imipenem 1.28 0.1 0.1 - 0 
K. pneumoniae 
Gentamicin - 7.5 5.5 - 4.4 
Amikacin 12.1 - - - - 
Piperacillin/Tazobactam 24.2 16.9 4.8 8.30 4.9 
Cotrimoxazol - - 15.5 12.5 9.3 
Ceftazidime - 12.1 6.1 13.3 7.6 
Ciprofloxacin - 10.9 5 16.7 10.3 
Imipenem 7.26 1.5 1.1 - 0.5 
P. aeruginosa 
Gentamicin - - - - 8.6 
Amikacin 25.25 - - - 0.5 
Piperacillin/Tazobactam 25.59 - - 8 4.9 
Cotrimoxazol - - - - - 
Ceftazidime - 7.4 - 12.70 4.4 
Ciprofloxacin - - - 21.10 11.3 
Imipenem 15.82 11.5 - 4.20 9.3 
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